Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice

FASEB Journal

Volumn 20, Issue 7, 2006, Pages

  Bilsland, Lynsey G ^a   Dick, James R T ^a   Pryce, Gareth ^a   Petrosino, Stefania ^b   Di Marzo, Vincenzo ^b   Baker, David ^a   Greensmith, Linda ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Endocannabinoids; Motoneuron; Neurodegeneration; Transgenic mice; WIN55,212 2

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; AMIDASE; CELL SURFACE RECEPTOR; FATTY-ACID AMIDE HYDROLASE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; NERVE CELL ADHESION MOLECULE; NEUROPEPTIDE; PCDHA4 PROTEIN, MOUSE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; GENETIC MANIPULATION; HISTOCHEMISTRY; MOTONEURON; MOUSE; MUSCLE FATIGUE; MUSCLE TWITCH; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CYTOLOGY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; LONGEVITY; MALE; METABOLISM; MOUSE MUTANT; SKELETAL MUSCLE; TRANSGENIC MOUSE;

MUS MUSCULUS;

AMIDOHYDROLASES; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CANNABINOIDS; CELL ADHESION MOLECULES, NEURONAL; DISEASE PROGRESSION; FEMALE; HUMANS; LONGEVITY; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MORPHOLINES; MOTOR NEURONS; MUSCLE FATIGUE; MUSCLE, SKELETAL; NAPHTHALENES; NEUROPEPTIDES; RECEPTORS, CELL SURFACE; SUPEROXIDE DISMUTASE;

EID: 33845683331     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-4743fje     Document Type: Article

References (53)

1. Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749
2. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., and Deng, H. X. (1993) Mutations in Cu/Zn SOD gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
3. Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., and Deng, H. X. (1994) Motor neuron degeneration in mice that express a human Cu,Zn SOD mutation. Science 264, 1772-1775.
4. Bensimon, G., Lacomblez, L., and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585-591
5. Shen, M. and Thayer, S. A. (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462
6. Abood, M. E., Rizvi, G., Sallapudi, N., and McAllister, S. D. (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309, 197-201
7. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutierrez, S. O., van der Stelt. M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo., V, Behl, C., and Lutz, B. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88
8. Pryce, G., Ahmed, Z., Hankey, D. J., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., Cuzner, M. L., and Baker, D. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202
9. Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., and Greenberg, D. A. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995
10. Molina-Holgado, F., Lledo, A., and Guaza, C. (1997) Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933
11. Puffenbarger, R. A., Boothe, A. C., and Cabral, G. A. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69
12. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., and Di, M., V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302
13. Klegeris, A., Bissonnette, C. J., and McGeer, P. L. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139, 775-786
14. Molina-Holgado, F., Pinteaux, E., Moore, J. D., Molina-Holgado, E., Guaza, C., Gibson, R. M., and Rothwell, N. J. (2003) Endogenous interleukin-1 receptor antagonist mediates antiinflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470-6474
15. Panikashvili, D., Simeonidou, C., Ben Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531
16. Di Marzo., V, Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691
17. Cadas, H., Gaillet, S., Beltramo, M., Venance, L., and Piomelli, D. (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16, 3934-3942
18. Sugiura, T., Yoshinaga, N., Kondo, S., Waku, K., and Ishima, Y. (2000) Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem. Biophys. Res. Commun. 271, 654-658
19. Hansen, H. H., Schmid, P. C., Bittigau, P., Lastres-Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H. H., Fernandez-Ruiz, J. J., and Hansen, H. S. (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415-1427
20. Hampson, A. J., Bornheim, L. M., Scanziani, M., Yost, C. S., Gray, A. T., Hansen, B. M., Leonoudakis, D. J., and Bickler, P. E. (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70, 671-676
21. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., and Lichtman, A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371-9376
22. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., Bohme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., Vassart, G., Fratta, W., and Parmentier, M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404
23. Di Marzo., V, Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., and Martin, B. R. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444
24. Kieran, D. and Greensmith, L. (2004) Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience 125, 427-439
25. Culling, C. F. A. (1963) Handbook of Histopathological Techniques, 2nd edition. pp 362-363. Butterworths: London, UK
26. Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., and Stella, N. (2004) Endocannabinoids accumulate in spinal cord of SOD1 transgenic mice. J. Neurochem. 89, 1555-1557
27. Sharp, P. S., Dick, J. R., and Greensmith, L. (2005) The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience 130, 897-910
28. Canton, T., Bohme, G. A., Boireau, A., Bordier, F., Mignani, S., Jimonet, P., Jahn, G., Alavijeh, M., Stygall, J., Roberts, S., Brealey, C., Vuilhorgne, M., Debono, M. W., Le Guern, S., Laville, M., Briet, D., Roux, M., Stutzmann, J. M., and Pratt, J. (2001) RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 299, 314-322
29. Van Damme, P., Leyssen, M., Callewaert, G., Robberecht, W., and Van den Bosch. L. (2003) The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 343, 81-84
30. Walter, L. and Stella, N. (2004) Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141, 775-785
31. Hampson, A. J., Grimaldi, M., Axelrod, J., and Wink, D. (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268-8273
32. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., and Behl, C. (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80, 448-456
33. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583
34. Raman, C., McAllister, S. D., Rizvi, G., Patel, S. G., Moore, D. H., and Abood, M. E. (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 5, 33-39
35. Weydt, P., Hong, S., Witting, A., Stella, N., Moeller, T., and Kliot, M. (2003) Assessing disease onset and progression in the SOD1 mouse model of ALS - effects of the nonpsychotropic cannabinoid cannabinol. Program No. 528.15, 2003 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 2003, Online; http://web.sfa.org/ACSplash
36. Hansen, H. H., Azcoitia, I., Pons, S., Romero, J., Garcia-Segura, L. M., Ramos, J. A., Hansen, H. S., and Fernandez-Ruiz, J. (2002) Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem. 82, 154-158
37. van der Stelt. M., Veldhuis, W. B., van Haaften, G. W., Fezza, F., Bisogno, T., Bar, P. R., Veldink, G. A., Vliegenthart, J. F., Di Marzo., V, and Nicolay, K. (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765-8771
38. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., and Leon, A. (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161-168
39. McGeer, P. L. and McGeer, E. G. (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470
40. Yasojima, K., Tourtellotte, W. W., McGeer, E. G., and McGeer, P. L. (2001) Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57, 952-956
41. Maihofner, C., Probst-Cousin, S., Bergmann, M., Neuhuber, W., Neundorfer, B., and Heuss, D. (2003) Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur. J. Neurosci. 18, 1527-1534
42. Hall, E. D., Oostveen, J. A., and Gurney, M. E. (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256
43. Alexianu, M. E., Kozovska, M., and Appel, S. H. (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282-1289
44. Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., Gullans, S., Ferrante, R. J., Przedborski, S., Kristal, B. S., and Friedlander, R. M. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78
45. Arevalo-Martin, A., Vela, J. M., Molina-Holgado, E., Borrell, J., and Guaza, C. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23, 2511-2516
46. Tikka, T. M., Vartiainen, N. E., Goldsteins, G., Oja, S. S., Andersen, P. M., Marklund, S. L., and Koistinaho, J. (2002) Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125, 722-731
47. Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., and Pasinetti, G. M. (2003) A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17, 725-727
48. Drachman, D. B., Frank, K., Dykes-Hoberg, M., Teismann, P., Almer, G., Przedborski, S., and Rothstein, J. D. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52, 771-778
49. Cudkowicz, M., Shefner, J., Schoenfeld, D., Rothstein, J. D., Drachman, D. B., and Northeast, A. L. S. (2004) Consortium NEALS. Clinical trial of celecoxib in subjects with amyotropic lateral sclerosis. amyotroph.lateral. scler.other motor neuron disord. 5 Supplement 2
50. Hajos, N., Ledent, C., and Freund, T. F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1-4
51. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G. L., Sibaev, A., Storr, M., and Lutz, B. (2004) The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209
52. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., and Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76-81
53. Kieran, D., Kalmar, B., Dick, J. R., Riddoch-Contreras, J., Burnstock, G., and Greensmith, L. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 10, 402-405